Please Wait...

Financial Compliance

ClinPay Supports the Sunshine Act and Sarbanes-Oxley

We crafted our clinical trial management solutions to meet direct reporting needs in accordance with Sunshine Act requirements. We support mandated site invoicing, which satisfies several Sarbanes-Oxley related compliance concerns.

ClinPay maintains NPI numbers for both the principal investigator (PI) and the health care provider (HCP) that is receiving payment. This is critical as the proposed guidelines for reporting require payments made to an HCP (teaching hospitals) be reported as "direct" and payments associated with the PI also be reported as "indirect" as they are associated with the payment; however, they are not the direct recipient of the payment.

Additionally, PIs can change during the course of a study and ClinPay allows PIs, along with other team members, to be maintained with a start and stop date. The system will adjust the transactions to be associated with the applicable PI.

Our ClinPay solution has the ability to track NPI numbers by PI, HCP, or institution and can be configured to meet varying needs.

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Great advice from our Dir. Cardiovascular Imaging on how to achieve top quality imaging acquisitions & assessments… https://t.co/P57970FrOf
bioclinica (18 hours ago)
RT @CenterWatch: #CWWeekly: The increasing trend of adopting digital health and #mhealth apps for patient care. Read more, https://t.co/wo9…
bioclinica (19 hours ago)
RT @CenterWatch: Examining the difference between #patient engagement & patient recruitment. Read more in #CWPulse by @AshleyTointon, https…
bioclinica (19 hours ago)
RT @CenterWatch: How can #socialmedia play a role in health disparities and #clinicaltrial patient recruitment? Read more in #CWPulse by @A…
bioclinica (19 hours ago)
RT @RAPSorg: What New @FDAcdrhIndustry Guidance is Coming in FY 2018: Alternative 510(k) Pathway and More | #Regulatory Recon https://t.co/…
bioclinica (19 hours ago)
RT @RAPSorg: .@US_FDA Finalizes Guidance on Promotional Drug Labeling and Ads | #Regulatory Focus https://t.co/2rmtTWajlf #FDA #pharma
bioclinica (19 hours ago)

Latest Blogs:

Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen
Congressman Meehan and Bioclinica CEO John Hubbard at recent visit to Bioclinica's Audubon offices